Copyright Reports & Markets. All rights reserved.

Global VEGF Inhibitors Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032

Request for Sample of this report
Buy now

1 Market Overview

  • 1.1 Product Overview and Scope
  • 1.2 Market Estimation Caveats and Base Year
  • 1.3 Market Analysis by Type
    • 1.3.1 Overview: Global VEGF Inhibitors Consumption Value by Type: 2021 Versus 2025 Versus 2032
    • 1.3.2 Monoclonal Antibodies
    • 1.3.3 Fusion Proteins
  • 1.4 Market Analysis by Application
    • 1.4.1 Overview: Global VEGF Inhibitors Consumption Value by Application: 2021 Versus 2025 Versus 2032
    • 1.4.2 Degenerative Eye Diseases
    • 1.4.3 Cancer
    • 1.4.4 Other
  • 1.5 Global VEGF Inhibitors Market Size & Forecast
    • 1.5.1 Global VEGF Inhibitors Consumption Value (2021 & 2025 & 2032)
    • 1.5.2 Global VEGF Inhibitors Sales Quantity (2021-2032)
    • 1.5.3 Global VEGF Inhibitors Average Price (2021-2032)

2 Manufacturers Profiles

  • 2.1 Roche
    • 2.1.1 Roche Details
    • 2.1.2 Roche Major Business
    • 2.1.3 Roche VEGF Inhibitors Product and Services
    • 2.1.4 Roche VEGF Inhibitors Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.1.5 Roche Recent Developments/Updates
  • 2.2 Novartis
    • 2.2.1 Novartis Details
    • 2.2.2 Novartis Major Business
    • 2.2.3 Novartis VEGF Inhibitors Product and Services
    • 2.2.4 Novartis VEGF Inhibitors Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.2.5 Novartis Recent Developments/Updates
  • 2.3 Coherus BioSciences
    • 2.3.1 Coherus BioSciences Details
    • 2.3.2 Coherus BioSciences Major Business
    • 2.3.3 Coherus BioSciences VEGF Inhibitors Product and Services
    • 2.3.4 Coherus BioSciences VEGF Inhibitors Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.3.5 Coherus BioSciences Recent Developments/Updates
  • 2.4 Bayer
    • 2.4.1 Bayer Details
    • 2.4.2 Bayer Major Business
    • 2.4.3 Bayer VEGF Inhibitors Product and Services
    • 2.4.4 Bayer VEGF Inhibitors Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.4.5 Bayer Recent Developments/Updates
  • 2.5 Amneal Pharmaceuticals
    • 2.5.1 Amneal Pharmaceuticals Details
    • 2.5.2 Amneal Pharmaceuticals Major Business
    • 2.5.3 Amneal Pharmaceuticals VEGF Inhibitors Product and Services
    • 2.5.4 Amneal Pharmaceuticals VEGF Inhibitors Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.5.5 Amneal Pharmaceuticals Recent Developments/Updates
  • 2.6 Sanofi
    • 2.6.1 Sanofi Details
    • 2.6.2 Sanofi Major Business
    • 2.6.3 Sanofi VEGF Inhibitors Product and Services
    • 2.6.4 Sanofi VEGF Inhibitors Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.6.5 Sanofi Recent Developments/Updates
  • 2.7 Samsung Bioepis
    • 2.7.1 Samsung Bioepis Details
    • 2.7.2 Samsung Bioepis Major Business
    • 2.7.3 Samsung Bioepis VEGF Inhibitors Product and Services
    • 2.7.4 Samsung Bioepis VEGF Inhibitors Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.7.5 Samsung Bioepis Recent Developments/Updates
  • 2.8 Eli Lilly
    • 2.8.1 Eli Lilly Details
    • 2.8.2 Eli Lilly Major Business
    • 2.8.3 Eli Lilly VEGF Inhibitors Product and Services
    • 2.8.4 Eli Lilly VEGF Inhibitors Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.8.5 Eli Lilly Recent Developments/Updates
  • 2.9 Pfizer
    • 2.9.1 Pfizer Details
    • 2.9.2 Pfizer Major Business
    • 2.9.3 Pfizer VEGF Inhibitors Product and Services
    • 2.9.4 Pfizer VEGF Inhibitors Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.9.5 Pfizer Recent Developments/Updates
  • 2.10 Celltrion Healthcare
    • 2.10.1 Celltrion Healthcare Details
    • 2.10.2 Celltrion Healthcare Major Business
    • 2.10.3 Celltrion Healthcare VEGF Inhibitors Product and Services
    • 2.10.4 Celltrion Healthcare VEGF Inhibitors Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.10.5 Celltrion Healthcare Recent Developments/Updates
  • 2.11 Amgen
    • 2.11.1 Amgen Details
    • 2.11.2 Amgen Major Business
    • 2.11.3 Amgen VEGF Inhibitors Product and Services
    • 2.11.4 Amgen VEGF Inhibitors Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.11.5 Amgen Recent Developments/Updates
  • 2.12 Chengdu Kanghong Pharmaceutical
    • 2.12.1 Chengdu Kanghong Pharmaceutical Details
    • 2.12.2 Chengdu Kanghong Pharmaceutical Major Business
    • 2.12.3 Chengdu Kanghong Pharmaceutical VEGF Inhibitors Product and Services
    • 2.12.4 Chengdu Kanghong Pharmaceutical VEGF Inhibitors Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.12.5 Chengdu Kanghong Pharmaceutical Recent Developments/Updates

3 Competitive Environment: VEGF Inhibitors by Manufacturer

  • 3.1 Global VEGF Inhibitors Sales Quantity by Manufacturer (2021-2026)
  • 3.2 Global VEGF Inhibitors Revenue by Manufacturer (2021-2026)
  • 3.3 Global VEGF Inhibitors Average Price by Manufacturer (2021-2026)
  • 3.4 Market Share Analysis (2025)
    • 3.4.1 Producer Shipments of VEGF Inhibitors by Manufacturer Revenue ($MM) and Market Share (%): 2025
    • 3.4.2 Top 3 VEGF Inhibitors Manufacturer Market Share in 2025
    • 3.4.3 Top 6 VEGF Inhibitors Manufacturer Market Share in 2025
  • 3.5 VEGF Inhibitors Market: Overall Company Footprint Analysis
    • 3.5.1 VEGF Inhibitors Market: Region Footprint
    • 3.5.2 VEGF Inhibitors Market: Company Product Type Footprint
    • 3.5.3 VEGF Inhibitors Market: Company Product Application Footprint
  • 3.6 New Market Entrants and Barriers to Market Entry
  • 3.7 Mergers, Acquisition, Agreements, and Collaborations

4 Consumption Analysis by Region

  • 4.1 Global VEGF Inhibitors Market Size by Region
    • 4.1.1 Global VEGF Inhibitors Sales Quantity by Region (2021-2032)
    • 4.1.2 Global VEGF Inhibitors Consumption Value by Region (2021-2032)
    • 4.1.3 Global VEGF Inhibitors Average Price by Region (2021-2032)
  • 4.2 North America VEGF Inhibitors Consumption Value (2021-2032)
  • 4.3 Europe VEGF Inhibitors Consumption Value (2021-2032)
  • 4.4 Asia-Pacific VEGF Inhibitors Consumption Value (2021-2032)
  • 4.5 South America VEGF Inhibitors Consumption Value (2021-2032)
  • 4.6 Middle East & Africa VEGF Inhibitors Consumption Value (2021-2032)

5 Market Segment by Type

  • 5.1 Global VEGF Inhibitors Sales Quantity by Type (2021-2032)
  • 5.2 Global VEGF Inhibitors Consumption Value by Type (2021-2032)
  • 5.3 Global VEGF Inhibitors Average Price by Type (2021-2032)

6 Market Segment by Application

  • 6.1 Global VEGF Inhibitors Sales Quantity by Application (2021-2032)
  • 6.2 Global VEGF Inhibitors Consumption Value by Application (2021-2032)
  • 6.3 Global VEGF Inhibitors Average Price by Application (2021-2032)

7 North America

  • 7.1 North America VEGF Inhibitors Sales Quantity by Type (2021-2032)
  • 7.2 North America VEGF Inhibitors Sales Quantity by Application (2021-2032)
  • 7.3 North America VEGF Inhibitors Market Size by Country
    • 7.3.1 North America VEGF Inhibitors Sales Quantity by Country (2021-2032)
    • 7.3.2 North America VEGF Inhibitors Consumption Value by Country (2021-2032)
    • 7.3.3 United States Market Size and Forecast (2021-2032)
    • 7.3.4 Canada Market Size and Forecast (2021-2032)
    • 7.3.5 Mexico Market Size and Forecast (2021-2032)

8 Europe

  • 8.1 Europe VEGF Inhibitors Sales Quantity by Type (2021-2032)
  • 8.2 Europe VEGF Inhibitors Sales Quantity by Application (2021-2032)
  • 8.3 Europe VEGF Inhibitors Market Size by Country
    • 8.3.1 Europe VEGF Inhibitors Sales Quantity by Country (2021-2032)
    • 8.3.2 Europe VEGF Inhibitors Consumption Value by Country (2021-2032)
    • 8.3.3 Germany Market Size and Forecast (2021-2032)
    • 8.3.4 France Market Size and Forecast (2021-2032)
    • 8.3.5 United Kingdom Market Size and Forecast (2021-2032)
    • 8.3.6 Russia Market Size and Forecast (2021-2032)
    • 8.3.7 Italy Market Size and Forecast (2021-2032)

9 Asia-Pacific

  • 9.1 Asia-Pacific VEGF Inhibitors Sales Quantity by Type (2021-2032)
  • 9.2 Asia-Pacific VEGF Inhibitors Sales Quantity by Application (2021-2032)
  • 9.3 Asia-Pacific VEGF Inhibitors Market Size by Region
    • 9.3.1 Asia-Pacific VEGF Inhibitors Sales Quantity by Region (2021-2032)
    • 9.3.2 Asia-Pacific VEGF Inhibitors Consumption Value by Region (2021-2032)
    • 9.3.3 China Market Size and Forecast (2021-2032)
    • 9.3.4 Japan Market Size and Forecast (2021-2032)
    • 9.3.5 South Korea Market Size and Forecast (2021-2032)
    • 9.3.6 India Market Size and Forecast (2021-2032)
    • 9.3.7 Southeast Asia Market Size and Forecast (2021-2032)
    • 9.3.8 Australia Market Size and Forecast (2021-2032)

10 South America

  • 10.1 South America VEGF Inhibitors Sales Quantity by Type (2021-2032)
  • 10.2 South America VEGF Inhibitors Sales Quantity by Application (2021-2032)
  • 10.3 South America VEGF Inhibitors Market Size by Country
    • 10.3.1 South America VEGF Inhibitors Sales Quantity by Country (2021-2032)
    • 10.3.2 South America VEGF Inhibitors Consumption Value by Country (2021-2032)
    • 10.3.3 Brazil Market Size and Forecast (2021-2032)
    • 10.3.4 Argentina Market Size and Forecast (2021-2032)

11 Middle East & Africa

  • 11.1 Middle East & Africa VEGF Inhibitors Sales Quantity by Type (2021-2032)
  • 11.2 Middle East & Africa VEGF Inhibitors Sales Quantity by Application (2021-2032)
  • 11.3 Middle East & Africa VEGF Inhibitors Market Size by Country
    • 11.3.1 Middle East & Africa VEGF Inhibitors Sales Quantity by Country (2021-2032)
    • 11.3.2 Middle East & Africa VEGF Inhibitors Consumption Value by Country (2021-2032)
    • 11.3.3 Turkey Market Size and Forecast (2021-2032)
    • 11.3.4 Egypt Market Size and Forecast (2021-2032)
    • 11.3.5 Saudi Arabia Market Size and Forecast (2021-2032)
    • 11.3.6 South Africa Market Size and Forecast (2021-2032)

12 Market Dynamics

  • 12.1 VEGF Inhibitors Market Drivers
  • 12.2 VEGF Inhibitors Market Restraints
  • 12.3 VEGF Inhibitors Trends Analysis
  • 12.4 Porters Five Forces Analysis
    • 12.4.1 Threat of New Entrants
    • 12.4.2 Bargaining Power of Suppliers
    • 12.4.3 Bargaining Power of Buyers
    • 12.4.4 Threat of Substitutes
    • 12.4.5 Competitive Rivalry

13 Raw Material and Industry Chain

  • 13.1 Raw Material of VEGF Inhibitors and Key Manufacturers
  • 13.2 Manufacturing Costs Percentage of VEGF Inhibitors
  • 13.3 VEGF Inhibitors Production Process
  • 13.4 Industry Value Chain Analysis

14 Shipments by Distribution Channel

  • 14.1 Sales Channel
    • 14.1.1 Direct to End-User
    • 14.1.2 Distributors
  • 14.2 VEGF Inhibitors Typical Distributors
  • 14.3 VEGF Inhibitors Typical Customers

15 Research Findings and Conclusion

    16 Appendix

    • 16.1 Methodology
    • 16.2 Research Process and Data Source

    According to our (Global Info Research) latest study, the global VEGF Inhibitors market size was valued at US$ million in 2025 and is forecast to a readjusted size of US$ million by 2032 with a CAGR of %during review period.
    Vascular endothelial growth factor inhibitors,are a class of medications that work by blocking the action of vascular endothelial growth factor(VEGF).VEGF is a protein that plays a crucial role in the formation of new blood vessels(angiogenesis)in both normal and pathological conditions,such as cancer.In medical practice,VEGF inhibitors are primarily used as anti-angiogenic agents to treat cancers and certain eye conditions.
    This report is a detailed and comprehensive analysis for global VEGF Inhibitors market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
    Key Features:
    Global VEGF Inhibitors market size and forecasts, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2021-2032
    Global VEGF Inhibitors market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2021-2032
    Global VEGF Inhibitors market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2021-2032
    Global VEGF Inhibitors market shares of main players, shipments in revenue ($ Million), sales quantity (K Units), and ASP (US$/Unit), 2021-2026
    The Primary Objectives in This Report Are:
    To determine the size of the total market opportunity of global and key countries
    To assess the growth potential for VEGF Inhibitors
    To forecast future growth in each product and end-use market
    To assess competitive factors affecting the marketplace
    This report profiles key players in the global VEGF Inhibitors market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Roche, Novartis, Coherus BioSciences, Bayer, Amneal Pharmaceuticals, Sanofi, Samsung Bioepis, Eli Lilly, Pfizer, Celltrion Healthcare, etc.
    This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
    Market Segmentation
    VEGF Inhibitors market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
    Market segment by Type
    Monoclonal Antibodies
    Fusion Proteins
    Market segment by Application
    Degenerative Eye Diseases
    Cancer
    Other
    Major players covered
    Roche
    Novartis
    Coherus BioSciences
    Bayer
    Amneal Pharmaceuticals
    Sanofi
    Samsung Bioepis
    Eli Lilly
    Pfizer
    Celltrion Healthcare
    Amgen
    Chengdu Kanghong Pharmaceutical
    Market segment by region, regional analysis covers
    North America (United States, Canada, and Mexico)
    Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
    Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
    South America (Brazil, Argentina, Colombia, and Rest of South America)
    Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
    The content of the study subjects, includes a total of 15 chapters:
    Chapter 1, to describe VEGF Inhibitors product scope, market overview, market estimation caveats and base year.
    Chapter 2, to profile the top manufacturers of VEGF Inhibitors, with price, sales quantity, revenue, and global market share of VEGF Inhibitors from 2021 to 2026.
    Chapter 3, the VEGF Inhibitors competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
    Chapter 4, the VEGF Inhibitors breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2021 to 2032.
    Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2021 to 2032.
    Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2021 to 2026.and VEGF Inhibitors market forecast, by regions, by Type, and by Application, with sales and revenue, from 2027 to 2032.
    Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
    Chapter 13, the key raw materials and key suppliers, and industry chain of VEGF Inhibitors.
    Chapter 14 and 15, to describe VEGF Inhibitors sales channel, distributors, customers, research findings and conclusion.

    Buy now